請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99970完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王錦堂 | zh_TW |
| dc.contributor.advisor | Jin-Town Wang | en |
| dc.contributor.author | 顧成詣 | zh_TW |
| dc.contributor.author | Cheng-Yi KU | en |
| dc.date.accessioned | 2025-09-22T16:11:08Z | - |
| dc.date.available | 2025-09-23 | - |
| dc.date.copyright | 2025-09-22 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-08-05 | - |
| dc.identifier.citation | 1. Rendueles, O., Deciphering the role of the capsule of Klebsiella pneumoniae during pathogenesis: A cautionary tale. Mol Microbiol, 2020. 113(5): p. 883-8.
2. Carpenter, J.L., Klebsiella pulmonary infections: occurrence at one medical center and review. Rev Infect Dis, 1990. 12(4): p. 672-82. 3. Jean, S.S., et al., Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia. J Clin Med, 2020. 9(1). 4. Struve, C. and K.A. Krogfelt, Pathogenic potential of environmental Klebsiella pneumoniae isolates. Environ Microbiol, 2004. 6(6): p. 584-90. 5. Yinnon, A.M., et al., Klebsiella bacteraemia: community versus nosocomial infection. Qjm, 1996. 89(12): p. 933-41. 6. Guerra, M.E.S., et al., Klebsiella pneumoniae Biofilms and Their Role in Disease Pathogenesis. Front Cell Infect Microbiol, 2022. 12: p. 877995. 7. Nicolle, L.E., Catheter associated urinary tract infections. Antimicrob Resist Infect Control, 2014. 3: p. 23. 8. Ong, C.L., et al., Identification of type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation. J Bacteriol, 2008. 190(3): p. 1054-63. 9. Bandeira, M., et al., Exploring Dangerous Connections between Klebsiella pneumoniae Biofilms and Healthcare-Associated Infections. Pathogens, 2014. 3(3): p. 720-31. 10. Lewis, K., Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol, 2008. 322: p. 107-31. 11. Paczosa, M.K. and J. Mecsas, Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol Biol Rev, 2016. 80(3): p. 629-61. 12. Schembri, M.A., et al., Capsule and fimbria interaction in Klebsiella pneumoniae. Infect Immun, 2005. 73(8): p. 4626-33. 13. Wyres, K.L., et al., Identification of Klebsiella capsule synthesis loci from whole genome data. Microb Genom, 2016. 2(12): p. e000102. 14. Mori, M., et al., Identification of species and capsular types of Klebsiella clinical isolates, with special reference to Klebsiella planticola. Microbiol Immunol, 1989. 33(11): p. 887-95. 15. ØRskov, I., Serological investigations in the Klebsiella group. I. New capsule types. Acta Pathol Microbiol Scand, 1955. 36(5): p. 449-53. 16. Pan, Y.J., et al., Identification of three podoviruses infecting Klebsiella encoding capsule depolymerases that digest specific capsular types. Microb Biotechnol, 2019. 12(3): p. 472-86. 17. Chen, J., H. Zhang, and X. Liao, Hypervirulent Klebsiella pneumoniae. Infect Drug Resist, 2023. 16: p. 5243-49. 18. Walker, K.A., et al., A Klebsiella pneumoniae Regulatory Mutant Has Reduced Capsule Expression but Retains Hypermucoviscosity. mBio, 2019. 10(2). 19. Stone, T.J., et al., Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae: Is ESBL-targeted therapy always needed? Antimicrob Steward Healthc Epidemiol, 2023. 3(1): p. e47. 20. Karampatakis, T., K. Tsergouli, and P. Behzadi, Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options. Antibiotics (Basel), 2023. 12(2). 21. Bassetti, M., et al., Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther, 2018. 16(10): p. 749-61. 22. Miller, W.R. and C.A. Arias, ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol, 2024. 22(10): p. 598-616. 23. Antibiotic Resistance Threats in the United States, 2019. 2019, CDC: Internet. 24. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. 2022, CDC: Internet. 25. WHO Bacterial Priority Pathogens List, 2024. 2024, WHO. 26. 台灣醫療照護相關感染與抗藥性監測季報 2023年 第4季. 2024, 衛生福利部疾病管制署: 台灣. 27. Tian, D., et al., Prevalence of hypervirulent and carbapenem-resistant Klebsiella pneumoniae under divergent evolutionary patterns. Emerg Microbes Infect, 2022. 11(1): p. 1936-49. 28. Qi, Y., et al., ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J Antimicrob Chemother, 2011. 66(2): p. 307-12. 29. Liu, L., et al., Carbapenem-resistant Isolates of the Klebsiella pneumoniae Complex in Western China: The Common ST11 and the Surprising Hospital-specific Types. Clin Infect Dis, 2018. 67(suppl_2): p. S263-s265. 30. Li, Z., et al., Carbapenem-Resistant Klebsiella pneumoniae in Southwest China: Molecular Characteristics and Risk Factors Caused by KPC and NDM Producers. Infect Drug Resist, 2021. 14: p. 3145-58. 31. Cai, Z., et al., Clinical and Molecular Analysis of ST11-K47 Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae: A Strain Causing Liver Abscess. Pathogens, 2022. 11(6). 32. Li, Y.T., et al., Distinct evolution of ST11 KL64 Klebsiella pneumoniae in Taiwan. Front Microbiol, 2023. 14: p. 1291540. 33. Encyclopaedia, T.E.o., Bacteriophage. Britannica, 2024. 34. Hatfull, G.F. and R.W. Hendrix, Bacteriophages and their genomes. Curr Opin Virol, 2011. 1(4): p. 298-303. 35. Naureen, Z., et al., Bacteriophages presence in nature and their role in the natural selection of bacterial populations. Acta Biomed, 2020. 91(13-s): p. e2020024. 36. Kasman LM, P.L., Bacteriophages. 2022, StatPearls [Internet]: Treasure Island (FL): StatPearls Publishing. 37. Gummalla, V.S., et al., The Role of Temperate Phages in Bacterial Pathogenicity. Microorganisms, 2023. 11(3). 38. Eiserling, F.A., Bacteriophage Structure, in Comprehensive Virology Volume 13: Structure and Assembly: Primary, Secondary, Tertiary, and Quaternary Structures, H. Fraenkel-Conrat and R.R. Wagner, Editors. 1979, Springer US: Boston, MA. p. 543-80. 39. Haudiquet, M., et al., Capsules and their traits shape phage susceptibility and plasmid conjugation efficiency. Nat Commun, 2024. 15(1): p. 2032. 40. Yap, M.L., et al., Role of bacteriophage T4 baseplate in regulating assembly and infection. Proc Natl Acad Sci U S A, 2016. 113(10): p. 2654-9. 41. Nobrega, F.L., et al., Targeting mechanisms of tailed bacteriophages. Nat Rev Microbiol, 2018. 16(12): p. 760-73. 42. Wittebole, X., S. De Roock, and S.M. Opal, A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence, 2014. 5(1): p. 226-35. 43. Abedon, S.T. and C. Thomas-Abedon, Phage therapy pharmacology. Curr Pharm Biotechnol, 2010. 11(1): p. 28-47. 44. Kutateladze, M. and R. Adamia, Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in Biotechnology, 2010. 28(12): p. 591-5. 45. Fujiki, J. and B. Schnabl, Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases. JHEP Rep, 2023. 5(12): p. 100909. 46. Federici, S., S.P. Nobs, and E. Elinav, Phages and their potential to modulate the microbiome and immunity. Cell Mol Immunol, 2021. 18(4): p. 889-904. 47. Yoo, S., et al., Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant Klebsiella pneumoniae. Microbiol Spectr, 2024. 12(1): p. e0125823. 48. Lin, D.M., B. Koskella, and H.C. Lin, Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther, 2017. 8(3): p. 162-73. 49. Hyman, P., Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth. Pharmaceuticals (Basel), 2019. 12(1). 50. Sulakvelidze, A., Z. Alavidze, and J.G. Morris, Jr., Bacteriophage therapy. Antimicrob Agents Chemother, 2001. 45(3): p. 649-59. 51. Liu, S., et al., Phages against Pathogenic Bacterial Biofilms and Biofilm-Based Infections: A Review. Pharmaceutics, 2022. 14(2). 52. Yang, Q., et al., Regulations of phage therapy across the world. Front Microbiol, 2023. 14: p. 1250848. 53. Nannapaneni, R. and K.A. Soni, Use of Bacteriophages to Remove Biofilms of Listeria monocytogenes and other Foodborne Bacterial Pathogens in the Food Environment, in Biofilms in the Food Environment. 2015. p. 131-44. 54. Monk, A.B., et al., Bacteriophage applications: where are we now? Lett Appl Microbiol, 2010. 51(4): p. 363-9. 55. Endersen, L., et al., Phage therapy in the food industry. Annu Rev Food Sci Technol, 2014. 5: p. 327-49. 56. Schofield, D.A., et al., Bacillus anthracis diagnostic detection and rapid antibiotic susceptibility determination using 'bioluminescent' reporter phage. J Microbiol Methods, 2013. 95(2): p. 156-61. 57. Latka, A., et al., Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol, 2017. 101(8): p. 3103-19. 58. Arato, V., et al., Prophylaxis and Treatment against Klebsiella pneumoniae: Current Insights on This Emerging Anti-Microbial Resistant Global Threat. Int J Mol Sci, 2021. 22(8). 59. Drulis-Kawa, Z., G. Majkowska-Skrobek, and B. Maciejewska, Bacteriophages and phage-derived proteins--application approaches. Curr Med Chem, 2015. 22(14): p. 1757-73. 60. Klumpp, J., M. Dunne, and M.J. Loessner, A perfect fit: Bacteriophage receptor-binding proteins for diagnostic and therapeutic applications. Curr Opin Microbiol, 2023. 71: p. 102240. 61. Zeineldin, M., et al., Beyond the Risk of Biofilms: An Up-and-Coming Battleground of Bacterial Life and Potential Antibiofilm Agents. Life (Basel), 2023. 13(2). 62. Vukotic, G., et al., Characterization, Antibiofilm, and Depolymerizing Activity of Two Phages Active on Carbapenem-Resistant Acinetobacter baumannii. Front Med (Lausanne), 2020. 7: p. 426. 63. Nazir, A., et al., Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients. Microorganisms, 2023. 11(2). 64. Guo, Z., M. Liu, and D. Zhang, Potential of phage depolymerase for the treatment of bacterial biofilms. Virulence, 2023. 14(1): p. 2273567. 65. Lin, T.L., et al., Development of Klebsiella pneumoniae Capsule Polysaccharide-Conjugated Vaccine Candidates Using Phage Depolymerases. Front Immunol, 2022. 13: p. 843183. 66. Li, J., et al., Ackermannviridae bacteriophage against carbapenem-resistant Klebsiella pneumoniae of capsular type 64. Front Microbiol, 2024. 15: p. 1462459. 67. Townsend, E.M., et al., Isolation and Characterization of Klebsiella Phages for Phage Therapy. Phage (New Rochelle), 2021. 2(1): p. 26-42. 68. Wu, J.W., et al., Identification of three capsule depolymerases in a bacteriophage infecting Klebsiella pneumoniae capsular types K7, K20, and K27 and therapeutic application. J Biomed Sci, 2023. 30(1): p. 31. 69. Latka, A., et al., Modeling the Architecture of Depolymerase-Containing Receptor Binding Proteins in Klebsiella Phages. Front Microbiol, 2019. 10: p. 2649. 70. Klumpp, J., D.E. Fouts, and S. Sozhamannan, Next generation sequencing technologies and the changing landscape of phage genomics. Bacteriophage, 2012. 2(3): p. 190-9. 71. Francis, D.M. and R. Page, Strategies to optimize protein expression in E. coli. Curr Protoc Protein Sci, 2010. Chapter 5(1): p. 5.24.1-5.24.29. 72. Pouresmaeil, M. and S. Azizi-Dargahlou, Factors involved in heterologous expression of proteins in E. coli host. Arch Microbiol, 2023. 205(5): p. 212. 73. Liu, Y., et al., Identification of Two Depolymerases From Phage IME205 and Their Antivirulent Functions on K47 Capsule of Klebsiella pneumoniae. Front Microbiol, 2020. 11: p. 218. 74. Li, M., et al., Identification of a phage-derived depolymerase specific for KL47 capsule of Klebsiella pneumoniae and its therapeutic potential in mice. Virol Sin, 2022. 37(4): p. 538-46. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99970 | - |
| dc.description.abstract | 在人類和致病菌的戰爭中，抗生素一直是最有力的武器，然而抗生素的濫用使得臨床上有越來越多多重抗藥性的菌株被發現，其中克雷伯氏肺炎桿菌（Klebsiella pneumoniae）以其厚重的莢膜與不俗的生物膜生成能力，造成棘手的院內感染，K47莢膜型（Capsular types）的克雷伯氏肺炎桿菌更是攻破目前抗生素最後防線的碳青黴烯（Carbapenem），發展出抗藥性。噬菌體（Bacteriophage）作為細菌最古老的宿敵，相較於抗生素有著專一性殺菌、迭代速度快、能夠清除生物膜等優點。在抗藥性菌株越發氾濫的情況下，以噬菌體進行殺菌的噬菌體療法（Phage therapy）無疑是個優秀的替代方案。在針對克雷伯氏肺炎桿菌的部分，有些噬菌體可以透過自身帶有的專一性莢膜分解酵素（Capsule depolymerase）突破菌株生物膜與莢膜，達成入侵宿主的目標。
本研究首先從環境廢水中純化出針對K47莢膜型的噬菌體，並透過點試驗檢測宿主範圍、觀察單一型態溶菌斑的雙圈呈現情形以及限制性片段長度多態性驗證初步判定是否與其它噬菌體相同，找到能感染多種K47菌株，且具有明顯雙圈溶菌斑的噬菌體ΦK47_1和ΦK47_4。後續於毒殺試驗與抗生物膜試驗中，確認了ΦK47_1和ΦK47_4皆有不錯的殺菌效果以及優秀的生物膜清除能力。於是將ΦK47_1和ΦK47_4基因體萃取出來後進行全基因體定序。在與美國國家生物技術資訊中心資料庫比對後，於ΦK47_1中找到可能編碼具有莢膜分解酵素活性蛋白的CDS_001、CDS_003、CDS_005、CDS_007與CDS_008，以此五段基因為模板進行基因重組蛋白的表現。其中序列比對為尾刺突蛋白（Tail spike protein）的CDS_003表現出來的重組蛋白Tsp03，能在對K47菌株產生溶菌斑，且能有效降解多醣。期望未來能進一步分析Tsp03與莢膜多醣反應的結構，以利進一步開發接合型疫苗（Conjugate vaccine）。 | zh_TW |
| dc.description.abstract | Antibiotics are the most powerful weapon in the war between humans and pathogenic bacteria. However, due to the misuse of antibiotics, more and more multi-drug-resistant strains have been discovered clinically, including Klebsiella pneumonia. This bacterium is famous for causing troublesome hospital-acquired infections with its thick capsule and excellent biofilm-generating ability. Moreover, the clinical data suggests that K47 capsular type K. pneumoniae gain carbapenem-resistant genes. This means that the antibiotics used as the last line of defense are no longer fully effective against K. pneumoniae. Therefore, it is imperative to find new treatments.Bacteriophages are the oldest enemies of bacteria. Compared with antibiotics, they have the advantages of specific targeting, fast iteration speed, and the ability to clear bacterial biofilms. As drug-resistant strains become increasingly prevalent, phage therapy, which uses phages to kill bacteria, is a brilliant alternative. For K. pneumoniae, some phages can break through the biofilm and capsule through their own specific targeting capsule depolymerases. This study first purified phages targeting the K47 type strains from environmental sewages. Next, phages were chosen based on whether they presented double-zone plaques and were tested for host range through spot tests. Restriction fragment length polymorphism (RFLP) was conducted to preliminarily determine whether they were the same as previously discovered phages. ΦK47_1 and ΦK47_4 were found, and their plaques presented obvious double zones. Killing assays and anti-biofilm tests confirmed that both ΦK47_1 and ΦK47_4 had good bactericidal effects and excellent biofilm removal capability. Therefore, the ΦK47_1 and ΦK47_4 genomes were extracted and subjected to whole genome sequencing. The sequencing data were aligned with the National Center for Biotechnology Information (NCBI) database. The results showed that five genes, CDS_001, CDS_003, CDS_005, CDS_007, and CDS_008, might have coded for proteins with capsule depolymerase activity. Hence, these five gene segments were selected as templates to express recombinant proteins. Among them, the recombinant protein Tsp03 produced lytic plaques on K47 strains in the spot test and effectively degraded capsular polysaccharide. The structure of the reaction between Tsp03 and capsular polysaccharide could be further analyzed in the future to facilitate the development of a conjugate vaccine. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-09-22T16:11:08Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-09-22T16:11:08Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 致謝 I
中文摘要 II Abstract III 目次 V 圖次 VII 表次 VIII 第一章 研究背景 1 1.1 克雷伯氏肺炎桿菌（Klebsiella pneumoniae） 1 1.2 噬菌體（Bacteriophages） 3 1.3 噬菌體療法（Phage therapy） 4 1.4 噬菌體莢膜分解酵素之臨床應用潛力 5 第二章 材料與方法 7 2.1 實驗材料 7 2.2 實驗方法 11 第三章 實驗結果 21 3.1 分離與純化K47莢膜型噬菌體 21 3.2 噬菌體宿主範圍試驗（Host range） 21 3.3 噬菌體基因體RFLP分析結果 22 3.4 噬菌體毒殺試驗 22 3.5 噬菌體抗生物膜試驗 22 3.6 噬菌體ΦK47_1、ΦK47_4全基因體定序結果 23 3.7 編碼莢膜分解酵素潛力之基因的選殖與表現結果 24 3.8 重組蛋白Tsp03萃取多醣降解試驗 25 第四章 討論與未來展望 26 參考文獻 29 附表 34 附圖 48 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 克雷伯氏肺炎桿菌 | zh_TW |
| dc.subject | 噬菌體 | zh_TW |
| dc.subject | 噬菌體療法 | zh_TW |
| dc.subject | 莢膜分解酵素 | zh_TW |
| dc.subject | 尾刺突蛋白 | zh_TW |
| dc.subject | Klebsiella pneumonia | en |
| dc.subject | Phage therapy | en |
| dc.subject | Capsule depolymerase | en |
| dc.subject | Tail spike protein | en |
| dc.subject | Bacteriophage | en |
| dc.title | 分離K47莢膜型克雷伯氏肺炎桿菌之噬菌體與其莢膜分解酵素功能分析 | zh_TW |
| dc.title | Isolation of a phage of K47 Klebsiella pneumoniae and characterization of its depolymerase | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 董馨蓮;潘怡均;許淳茹 | zh_TW |
| dc.contributor.oralexamcommittee | Xin-Lian Dong;Yi-Chun Pang;Chun-Ru Hsu | en |
| dc.subject.keyword | 克雷伯氏肺炎桿菌,噬菌體,噬菌體療法,莢膜分解酵素,尾刺突蛋白, | zh_TW |
| dc.subject.keyword | Klebsiella pneumonia,Bacteriophage,Phage therapy,Capsule depolymerase,Tail spike protein, | en |
| dc.relation.page | 65 | - |
| dc.identifier.doi | 10.6342/NTU202503706 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2025-08-05 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 微生物學研究所 | - |
| dc.date.embargo-lift | N/A | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 2.45 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。